\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	PROVAL
OMB Number:	3235-0287
Ectimated average	burdon

Estimated average burden	
hours per response:	0.5

1. Name and Address of Reporting Person* Landry Robert E			2. Issuer Name and Ticker or Trading Symbol <u>REGENERON PHARMACEUTICALS</u> <u>INC</u> [REGN]		ionship of Reporting Perso all applicable) Director Officer (give title below)	n(s) to Issuer 10% Owner Other (specify below)	
		· ,	3. Date of Earliest Transaction (Month/Day/Year) 08/05/2015		SVP Finance & 0	,	
(Street) TARRYTOWN NY 10591		10591	4. If Amendment, Date of Original Filed (Month/Day/Year)		vidual or Joint/Group Filing (Check Applicabl Form filed by One Reporting Person Form filed by More than One Reporting		
(City)	(State)	(Zip)			Person	-	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

	•									
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code V		Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	08/05/2015		М		4,000	A	\$272.7	11,099	D	
Common Stock	08/05/2015		S		400	D	\$591.78 ⁽¹⁾	10,699	D	
Common Stock	08/05/2015		S		1,500	D	\$592.36 ⁽²⁾	9,199	D	
Common Stock	08/05/2015		S		2,100	D	\$593.38 ⁽³⁾	7,099	D	
Common Stock								35	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$272.7	08/05/2015		М			4,000	(4)	09/09/2023	Common Stock	4,000	\$0.0	66,000	D	


Explanation of Responses:

1. Represents volume-weighted average price of sales of 400 shares of Company stock on August 5, 2015 at prices ranging from \$591.64 to \$591.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2015 at each separate price.

2. Represents volume-weighted average price of sales of 1,500 shares of Company stock on August 5, 2015 at prices ranging from \$592.02 to \$592.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2015 at each separate price.

3. Represents volume-weighted average price of sales of 2,100 shares of Company stock on August 5, 2015 at prices ranging from \$593.00 to \$593.67. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2015 at each separate price.

4. The stock option award vests in four equal annual installments, commencing one year after the date of grant.



08/06/2015 Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.